🇺🇸 Moxifloxacin (Avelox) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Abdominal Pain Upper — 1 report (10%)
  2. Cardiac Arrest — 1 report (10%)
  3. Central Nervous System Lesion — 1 report (10%)
  4. Clostridium Difficile Infection — 1 report (10%)
  5. Discomfort — 1 report (10%)
  6. Dizziness — 1 report (10%)
  7. Dyspnoea — 1 report (10%)
  8. Dyspnoea Exertional — 1 report (10%)
  9. Haemoglobin Decreased — 1 report (10%)
  10. Haemorrhage — 1 report (10%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Moxifloxacin (Avelox) approved in United States?

Moxifloxacin (Avelox) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Moxifloxacin (Avelox) in United States?

Connect Biopharma Australia Pty Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.